BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ:AKRX) today announced the signing of an exclusive drug development and supply agreement with Cipla, Ltd., a leading Indian pharmaceutical company located in Mumbai, India for an injectable ANDA drug product for the prevention of organ transplant rejection. In June 2007, Akorn previously announced the exclusive agreement for the oral dosage form of this drug product. The addition of the injectable format expands the breadth of Akorn’s offerings for this indication.
